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In multiple sclerosis (MS), soluble tumor necrosis
factor (TNF) is detrimental via activation of TNF re-
ceptor 1 (TNFR1), whereas transmembrane TNF is
beneficial primarily by activating TNF receptor 2
(TNFR2). Here, we investigate the role of TNFR2 in
microglia and monocytes/macrophages in experi-
mental autoimmune encephalomyelitis (EAE), a
model of MS, by cell-specific gene targeting. We
show that TNFR2 ablation in microglia leads to early
onset of EAE with increased leukocyte infiltration,
T cell activation, and demyelination in the central
nervous system (CNS). Conversely, TNFR2 ablation
in monocytes/macrophages results in EAE suppres-
sion with impaired peripheral T cell activation and
reduced CNS T cell infiltration and demyelination.
Our work uncovers a dichotomy of function for
TNFR2 in myeloid cells, with microglial TNFR2
providing protective signals to contain disease and
monocyte/macrophagic TNFR2 driving immune acti-
vation and EAE initiation. This must be taken into
account when targeting TNFR2 for therapeutic pur-
poses in neuroinflammatory diseases.
INTRODUCTION
Tumor necrosis factor (TNF) has been associated with the path-
ophysiology of multiple sclerosis (MS), because MS patients
have high TNF concentrations in active lesions and cerebrospi-
nal fluid, which correlate with the degree of disability (Hofman
et al., 1989; Sharief and Hentges, 1991). TNF exists in two forms,198 Cell Reports 18, 198–212, January 3, 2017 ª 2017 The Author(s)
This is an open access article under the CC BY-NC-ND license (http://transmembrane (tmTNF) and soluble (solTNF). solTNF derives
from cleavage of tmTNF by the TNF-alpha converting enzyme
(TACE). tmTNF signals via TNF receptor 1 (TNFR1; Tnfrsf1a)
and TNF receptor 2 (TNFR2; Tnfrsf1b), althoughwith higher affin-
ity for TNFR2, whereas solTNF signals via TNFR1 (Grell et al.,
1995; Wajant et al., 2003). TNFR1 is widely expressed and medi-
ates the majority of solTNF-dependent effects in inflammation,
apoptosis, and neurotoxicity (Probert, 2015). Expression of
TNFR2 is mostly restricted to immune and endothelial cells,
where it sustains T regulatory (Treg) function (Chen and Oppen-
heim, 2010), suppresses T helper (Th) 17 differentiation (Miller
et al., 2015), and promotes lymphocyte proliferation (Tartaglia
et al., 1993) and monocyte recruitment by endothelial cells (Ven-
katesh et al., 2013). In the central nervous system (CNS), TNFR2
is minimally expressed physiologically but is upregulated in mi-
croglia, astrocytes, and oligodendrocytes in neurological dis-
ease (Brambilla et al., 2011; Lambertsen et al., 2007). TNFR2 is
virtually absent in CNS neurons, both in normal and pathological
conditions (Brambilla et al., 2011; Probert, 2015), with motor
neurons in a rodent model of Amyotrophic Lateral Sclerosis
(ALS) (Veglianese et al., 2006) and a few neuron subsets in the
Alzheimer’s brain (Cheng et al., 2010) being the only exceptions
reported. TNFR2 has been suggested to play a role in neuropro-
tection and remyelination (Arnett et al., 2001; Fontaine et al.,
2002; Marchetti et al., 2004; Patel et al., 2012), but little is known
about its function in individual CNS cell lineages in vivo. Recent
studies from our lab have addressed this void by cell-specific
gene-targeting approaches, demonstrating that oligodendroglial
TNFR2 promotes oligodendrocyte differentiation and remyelina-
tion in experimental autoimmune encephalomyelitis (EAE), a
model of MS (Madsen et al., 2016b). Microglia and monocytes/
macrophages (Mo/MFs) play critical roles in MS and EAE
(Shemer and Jung, 2015), and both express TNFR2 (Brambilla
et al., 2011). However, the current knowledge of TNFR2 function.
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Ablation of Microglial TNFR2 in Cx3cr1CreER:Tnfrsf1bfl/fl Mice Leads to the Early Onset of EAE
(A) Clinical course of EAE in Tnfrsf1bfl/fl and Cx3cr1CreER:Tnfrsf1bfl/fl mice. n = 13–17/group from two experiments; **p% 0.01, one-way ANOVA, Mann-Whitney
test.
(B–E) Flow cytometric analysis of microglia in the spinal cord at 17 dpi EAE. Quantification of percentage (C) and number (D) of microglia, and percentage of
MHCII+ activated microglia (E). n = 5/group, *p% 0.05, Student’s t test.
(legend continued on next page)
Cell Reports 18, 198–212, January 3, 2017 199
in these populations is limited to only two in vitro studies: in mi-
croglia, TNFR2 was shown to promote the expression of antiin-
flammatory and neuroprotective genes (Veroni et al., 2010), and
in macrophages, to play an auxiliary role in activating proinflam-
matory TNFR1 signaling (Ruspi et al., 2014). Because TNFR2
function in microglia and Mo/MFs in neurological disease is
completely unknown, the goal of our study was to systematically
dissect the roles of TNFR2 in these populations in EAE etiopa-
thology. Using conditional knockout (cKO) models, we demon-
strated that microglial TNFR2 is protective in the early stages
of EAE, whereas monocyte/macrophagic TNFR2 is detrimental
and drives disease initiation. Ablation of microglial TNFR2 accel-
erated EAE onset by establishing a proinflammatory environ-
ment that increased T cell activation in the CNS. In contrast,
ablation of monocyte/macrophagic TNFR2 impaired T cell acti-
vation in the periphery, resulting in reduced CNS immune cell
infiltration and EAE suppression. Taken together, our data
demonstrate the opposite functions of TNFR2 signaling in micro-
glia and peripheral Mo/MFs in the pathophysiology of EAE. This
dichotomy needs to be addressed when targeting TNFR2
signaling for therapeutic purposes in MS or any other neuroin-
flammatory disease in which both cell populations are major
contributors.
RESULTS
Ablation of Microglial TNFR2 in Cx3cr1CreER:Tnfrsf1bfl/fl
Mice Leads to the Early Onset of EAE
Selective gene targeting in microglia has been challenging
because of their shared gene profile with Mo/MFs. To restrict
Tnfrsf1bfl/fl ablation to microglia, we generated Cx3cr1CreER:
Tnfrsf1bfl/fl cKO mice and adopted an established tamoxifen
(tam) induction protocol that exploits the different origins and
turnover rates of microglia versus other CX3CR1
+ myeloid cells
(Goldmann et al., 2013; Parkhurst et al., 2013). In this protocol,
five daily tam injections are followed by a 28-day waiting period
(instead of the usual 5–7 days) during which fast-renewing Mo/
MFs are replaced by wild-type (WT) cells derived from bone
marrow precursors, whereas self-renewing microglia are not re-
placed and maintain Tnfrsf1b ablation. Even though specific
microglial gene targeting has already been demonstrated with
this protocol (Goldmann et al., 2013; Parkhurst et al., 2013), we
still validated it in our own setting by comparison with a conven-
tional 5-day waiting period. To do so, we crossed Cx3cr1CreER
mice, which constitutively express enhanced yellow fluorescent
protein (EYFP) in CX3CR1
+ cells, with Rosa26tdTomato+/ re-
porters. In the spinal cord we detected recombination by
tdTomato fluorescence in almost 90% of EYFP+ microglia (Fig-(F) Representative flow plots of Ki67 expression in microglia at 17 dpi.
(G) Quantification of Ki67+ microglia. n = 4–5/group, **p% 0.01, Student’s t test
(H) Representative flow plots of Annexin V expression in microglia at 17 dpi.
(I) Quantification of Annexin V+PI and Annexin V+PI+ microglia. n = 4–5/group.
(J) Representative flow plots of CD4 and CD8 cells in the spinal cord at 17 dpi.
(K and L) Percentages (K) and absolute numbers (L) of infiltrated immune cells
*p% 0.05, **p% 0.01, Student’s t test.
(M) Representative flow plots of total and MHCII+ splenic B cells at 17 dpi.
(N and O) Percentages (N) and absolute numbers (O) of splenic immune cells. n
All graph bars represent SEM.
200 Cell Reports 18, 198–212, January 3, 2017ures S1A and S1C). In the spleen, recombination was decreased
from 40% to about 3% in EYFP+ myeloid cells 28 days after
tam injection, confirming that gene targeting was restricted
to CX3CR1
+ microglia and not Mo/MFs (Figures S1B and S1C).
TNFR2 was barely present in microglia in naive conditions
(less than 5%; Figures S2A–S2C) but was robustly upregulated
after EAE (Figures S2D–S2J) to about 70% in Tnfrsf1bfl/fl
mice and was reduced to 30% in Cx3cr1CreER:Tnfrsf1bfl/fl mice
(Figures S2D and S2E). Both splenic and CNS-infiltrated
Mo/MFs highly expressed TNFR2 after EAE (Figures S2F–
S2I) with no difference between genotypes. These data demon-
strate that Cx3cr1CreER:Tnfrsf1bfl/fl mice induced with the 28-
day tam protocol are an excellent model for selective TNFR2
ablation in microglia. Analysis with Rotorod and open-field
tests showed no abnormal locomotor phenotype (Figures S3A–
S3C) or altered spontaneous activity (Figures S3D–S3H) in
naive Cx3cr1CreER:Tnfrsf1bfl/fl mice. Furthermore, microglial
number was comparable with controls (Figure S3I), and so was
the expression of microglia-associated genes, such as Trem2
and P2ry12 (Figure S3J). Notably, microglial Tnfrsf1b, which is
minimally expressed in naive microglia (Figure S2A), did not
change between Tnfrsf1bfl/fl and Cx3cr1CreER:Tnfrsf1bfl/fl mice,
which explains the lack of phenotypical alterations in naive
animals.
Induced with EAE, Cx3cr1CreER:Tnfrsf1bfl/fl mice displayed
earlier disease onset, although the clinical course later overlap-
ped that of Tnfrsf1bfl/fl controls (Figure 1A; Table S1). At
17 days post induction (dpi), when the highest difference in clin-
ical scores was observed, Cx3cr1CreER:Tnfrsf1bfl/fl mice showed
more robust microglial activation. Indeed, CD45lowCD11b+ total
microglia (Figures 1B–1D) and major histocompatibility complex
II+ (MHCII+) activated microglia (Figures 1B and 1E) were signifi-
cantly increased. This was due to enhanced proliferation, as
shown by the higher number of Ki67+ microglia (Figures 1F and
1G), and not to an effect on survival, because the numbers
of propidium iodide (PI) Annexin V+ early apoptotic and PI+
Annexin V+ late apoptotic and necrotic microglia were compara-
ble between genotypes (Figures 1H and 1I). Analysis of immune
cell infiltration into the spinal cord showed a marked increase in
CD4 T cells and MHCII+ activated Mo/MFs in Cx3cr1CreER:
Tnfrsf1bfl/flmice (Figures 1J–1L), which correlatedwith the earlier
disease symptoms. Ly6G+ neutrophils and total andMHCII+ Mo/
MFs (Figure 1K) were significantly lower, likely because of faster
mobilization into circulation. Notably, Cx3cr1CreER:Tnfrsf1bfl/fl
mice had higher frequency of total and MHCII+ splenic B cells
(Figures 1M and 1N), which indicates increased antigen presen-
tation capacity and could explain, at least in part, the increased
expansion of CD4 T cells..
. Mo/MFs are defined as CD45hiCD11b+NK1.1Ly6GSSAlow. n = 5/group;
= 6/group; *p% 0.05, Student’s t test.
Figure 2. Ablation of Microglial TNFR2 Leads to Exacerbated T Cell Effector Function in the Spinal Cord after EAE
(A, B, D, E, G, and H) Representative flow plots of cytokine expression in CD4 (A, B, D, E) and CD8 (G, H) T cells isolated from spinal cord and spleen of Tnfrsf1bfl/fl
and Cx3cr1CreER:Tnfrsf1bfl/fl mice at 17 dpi; n = 4–5/group; *p% 0.05, Student’s t test.
(C, F, and I) Quantification of cytokine expression in CD4 (C, F) and CD8 (I) T cells from spinal cord and spleen; n = 4–5/group.
(J) Western blot analysis of tight junction proteins in the spinal cord at 12 dpi EAE; n = 4–9/group; **p% 0.01, Student’s t test.
All graph bars represent SEM.Ablation of Microglial TNFR2 Leads to Exacerbated
T Cell Effector Function in the Spinal Cord after EAE
BecauseEAEsymptomsare largely drivenbyactivatedTcells,we
tested T effector function by measuring Th1 and Th17 cytokines
after ex vivo restimulation. In the spinal cord, infiltrated CD4 cells
from Cx3cr1CreER:Tnfrsf1bfl/fl mice showed increased interleukin
(IL)-17 production (Figures 2A and 2C), but no changes in inter-
feron g (IFNg) and TNF (Figures 2A–2C). No differences were
found in splenicCD4 andCD8 cells (Figures 2D–2I). This suggeststhat TNFR2-ablated microglia establish an environment prone to
driving T cells toward Th17 differentiation in the CNS. Interest-
ingly, prior to disease onset (12 dpi), Cx3cr1CreER:Tnfrsf1bfl/fl
mice showed reduced expression of the tight junction protein
ZonaOcculdens-1 (ZO-1) in the spinal cord (Figure2J).By binding
toother tight junctionelements likeClaudin-5andOccludin,which
didnot change inourmodel (Figure2J), ZO-1playsacrucial role in
blood-brain barrier (BBB) integrity (Bennett et al., 2010), and its
downregulation is indicativeof increasedBBBpermeability,whichCell Reports 18, 198–212, January 3, 2017 201
Figure3. Microglial TNFR2AblationLeads to
Increased Demyelination with Chronic EAE
(A) Assessment of demyelination in the spinal cord
of Tnfrsf1bfl/fl and Cx3cr1CreER:Tnfrsf1bfl/fl mice by
LFB staining. Left: contoured areas show regions
of demyelinated white matter. Scale bars, 200 mm.
Right: 3D reconstructions of the demyelinated
areas (red).
(B) Quantification of the demyelinated white matter
volume. n = 3–5/group, *p% 0.05, Student’s t test.
(C andD)Quantification of Olig2+CC1+ cells (C) and
Olig2+PDGFRa+ cells (D) in the spinal cord. n = 3–5/
group; *p% 0.05, **p% 0.01, Student’s t test.
(E) Toluidine blue staining of spinal cord sections
from naive and 40 dpi mice. Red arrows indicate
degenerated collapsed axons. Scale bars, 10 mm.
(F and G) Quantification of myelinated (F) and
degenerated (G) axons. n = 4–5/group.
All graph bars represent SEM.could contribute to the increased immune cell infiltration in
Cx3cr1CreER:Tnfrsf1bfl/flmice (Figure 1L).
Ablation of Microglial TNFR2 Leads to Increased
Demyelination with Chronic EAE
Even though Cx3cr1CreER:Tnfrsf1bfl/fl and Tnfrsf1bfl/fl mice
showed overlapping clinical profiles at chronic EAE, analysis of
the spinal cord at 40 dpi revealed increased white matter dam-
age in Cx3cr1CreER:Tnfrsf1bfl/fl mice (Figures 3A and 3B). This
was paralleled by higher loss of Olig2+CC1+ oligodendrocytes
(Figure 3C) and an increase in Olig2+PDGFRa+ oligodendrocyte
precursor cells (OPCs) (Figure 3D). Increased OPC numbers
could depend on increased proliferation and survival to repair
myelin damage (Maier et al., 2013), or on impaired differentiation202 Cell Reports 18, 198–212, January 3, 2017into mature oligodendrocytes, because
TNFR2 has been shown to regulate this
process (Madsen et al., 2016b). Analysis
of axonal pathology showed no differ-
ence in the number of intact (Figures 3E
and 3F) or degenerated axons (Figures
3E and 3G). This may explain the similar
clinical scores at chronic disease despite
myelin damage being more severe in
Cx3cr1CreER:Tnfrsf1bfl/fl mice.
TNFR2-AblatedMicroglia Develop a
Proinflammatory Phenotype with
Dysregulated Expression of
Homeostatic and Host Defense
Genes after EAE
To dissect the mechanisms by which mi-
croglial TNFR2 regulates EAE pathogen-
esis, we analyzed the transcriptome
of spinal cord microglia from Tnfrsf1bfl/fl
and Cx3cr1CreER:Tnfrsf1bfl/fl mice at 17
dpi using RNA sequencing (RNA-seq)
(GEO: GSE78082). We found 5,049 differ-
entially expressed genes with high repro-ducibility across samples (Figure 4A); 20% were upregulated
(1,022 genes) and 80% downregulated (4,027 genes) in
Cx3cr1CreER:Tnfrsf1bfl/fl compared with Tnfrsf1bfl/fl mice (Fig-
ure 4A), including Tnfrsf1b (Figure 4C). Interestingly, Tnfrsf1a
did not change (Figure 4C; Figure S4A), indicating that microglial
TNFR2 does not have a modulatory function on TNFR1 at the
transcriptional level. Changes were validated by qPCR on select
genes and matched the RNA-seq data (Figure S4A). Most of the
downregulated genes belonged to pathways controlling cell ho-
meostasis, such as mitogen-activated protein kinase (MAPK)
and nuclear factor kB (NF-kB) (Figure 4B), and were found to
be physically or functionally connected with TNFR2 (Figure S4B).
Notably, the dysregulated genes includedmodulators of two key
aspects of microglia innate immune function: inflammation and
(legend on next page)
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host defense. With respect to inflammation, TNFR2-ablated
microglia showed upregulation of chemokines (Figure 4D), cell
adhesion molecules, oxidative enzymes, and growth factors
(Figure 4E), and downregulation of antiinflammatory signals like
Zfp36 and Socs3 (Figure 4F). With respect to host defense,
microglia from Cx3cr1CreER:Tnfrsf1bfl/fl mice showed dysregula-
tion of the ‘‘microglial sensome’’ (Hickman et al., 2013), a
set of molecules that define the microglial surveillance ma-
chinery. Only 7.1% of sensome genes were upregulated in
Cx3cr1CreER:Tnfrsf1bfl/fl mice and more than 46% were downre-
gulated (Figure 4G). These include receptors for pathogen
recognition (Fcgr3), phagocytosis (Trem2) (Figure 4H), and tissue
surveillance (purinergic and Siglec receptors; Figures 4I and 4J),
suggesting that without TNFR2, key homeostatic functions ofmi-
croglia may be altered. Phagocytosis was indeed compromised,
because cultured microglia from Tnfrsf1b/ mice showed a
reduced capacity to engulf fluorescent beads both in unstimu-
lated and in lipopolysaccharide (LPS)-stimulated conditions (Fig-
ures 4K and 4L). Importantly, Trem2 and P2ry12were reduced in
Tnfrsf1b/ unstimulated microglia (Figures 4M and 4N) and
further downregulated in both genotypes after LPS stimulation.
This suggests that TNFR2 activation is necessary for constitutive
expression of these genes. Trem2 and P2ry12 were also as-
sessed after stimulation with solTNF, which activates proinflam-
matory TNFR1. Unlike LPS, solTNF did not maintain suppression
of Trem2 and P2ry12 in Tnfrsf1b/ microglia (Figure S4C). This
indicates that transcriptional regulation of Trem2 and P2ry12 by
solTNF depends not only on direct TNFR1 activation, but also on
the auxiliary presence of TNFR2. The cooperative signaling of
TNFR1 and TNFR2 in myeloid cells also has been suggested in
previous reports (Ruspi et al., 2014).
Collectively, these data indicate that without TNFR2, microglia
develop a more invasive proinflammatory phenotype that accel-
erates EAE pathogenesis, while losing signals necessary to carry
out essential homeostatic functions, including tissue surveil-
lance and host defense.
Ablation of TNFR2 in LysMCre:Tnfrsf1bfl/flMiceResults in
Suppression of EAE
To assess TNFR2 function in Mo/MFs, we used LysMCre:
Tnfrsf1bfl/fl cKOs in combination with a bone marrow transplan-
tation strategy. To start, we tested LysMCre recombination
efficiency in peripheral and CNS myeloid cells by crossingFigure 4. RNA-Seq Analysis of the Microglial Transcriptome after EAE
(A) Heatmap of differentially expressed genes in spinal cord microglia sorted from
are expressed as log2 values. Red represents upregulated genes; blue represen
(B) DAVID pathway analysis of differentially expressed genes in Cx3cr1CreER:Tn
represents downregulated pathways. The p values are shown next to the bars.
(C–F and H) Gene expression profiles of TNF receptors (C), chemokines (D), pr
and sensome genes (H) from the RNA-seq analysis shown as fragments per kilo
****p% 0.0001, Student’s t test.
(G) Expression of microglial sensome genes in Cx3cr1CreER:Tnfrsf1bfl/fl versus Tn
(I and J) Expression of purinergic (I) and Siglec (J) receptors obtained from the R
(K and L) Quantification of microglial phagocytosis in vitro. Fluorescent beads
quantified in unstimulated conditions or after LPS treatment (L). n = 6/group; ***p
(M and N) Expression of Trem2 (M) and P2ry12 (N) in culturedmicroglia. n = 6/grou
Student’s t test.
All graph bars represent SEM. See also Figure S4.
204 Cell Reports 18, 198–212, January 3, 2017LysMCre+/ mice with Rosa26tdTomato+/ reporters. In splenic
myeloid cells, recombination was similar in naive and EAE con-
ditions reaching approximately 50% (Figures S5A and S5C). In
spinal cordmicroglia, recombination was inefficient in naive con-
ditions, with only 10% of CD11b+CX3CR1
+ cells positive for
tdTomato, which increased to 30% after EAE (Figures S5B and
S5D). TNFR2 expression, virtually absent in naive conditions
(Figures S2A and S2B), amounted to more than 60% of splenic
Mo/MFs and microglia in Tnfrsf1bfl/fl mice after EAE, and was
significantly reduced in both populations in LysMCre:Tnfrsf1bfl/fl
mice (Figures S5E, S5F, S5I, and S5J; Table S2). This was
confirmed by immunohistochemistry (Figure S5K). We also
confirmed that TNFR2 ablation did not interfere with TNFR1
expression in splenic Mo/MFs (Figures S5G and S5H). Because
the LysM promoter is active in granulocytes and other immune
cells (Goldmann et al., 2013), to assess specificity of myeloid
ablation, we measured TNFR2 expression in various splenic
populations (Table S2). TNFR2 was present in T cells, B cells,
and neutrophils with no difference between Tnfrsf1bfl/fl and
LysMCre:Tnfrsf1bfl/fl mice. In NKs, TNFR2 was upregulated after
EAE, with mild but significant reduction in LysMCre:Tnfrsf1bfl/fl
mice. This should not influence the LysMCre:Tnfrsf1bfl/fl pheno-
type because NKs represent only a small fraction of the splenic
population (less than 3%; Figure 5E). It is worth noting that
neuronal expression of Cre recombinase in LysMCre mice has
been reported by various groups including ours (Clausen et al.,
2016; Orthgiess et al., 2016). However, because TNFR2 is virtu-
ally absent in CNS neurons (Brambilla et al., 2011; Zhang et al.,
2014), neuronal Cre activity should not affect TNFR2 expression
in LysMCre:Tnfrsf1bfl/fl mice. Like Cx3cr1CreER:Tnfrsf1bfl/fl mice,
LysMCre:Tnfrsf1bfl/fl mice did not show alterations in locomotor
function, spontaneous activity, or splenic leukocyte profile
(Figure S6).
To test myeloid TNFR2 function, we induced EAE in Tnfrsf1bfl/fl
and LysMCre:Tnfrsf1bfl/fl mice. Contrary to Cx3Cr1CreER:
Tnfrsf1bfl/fl cKOs, EAE was markedly suppressed in LysMCre:
Tnfrsf1bfl/fl mice, with average scores less than 2 (flaccid tail,
but no paralysis) (Figure 5A; Table S3). Because TNFR2 ablation
occurs in both Mo/MFs and microglia in this model, to dissect
the contribution of each population to EAE development, we
generated bone marrow chimeras with gene ablation specific to
either Mo/MFs (LysMCre:Tnfrsf1bfl/fl/CD45.1) or microglia
(CD45.1/LysMCre:Tnfrsf1bfl/fl). In LysMCre:Tnfrsf1bfl/fl/CD45.1Cx3cr1CreER:Tnfrsf1bfl/fl and Tnfrsf1bfl/fl mice at 17 dpi; n = 4/group. Changes
ts downregulated genes.
frsf1bfl/fl versus Tnfrsf1bfl/fl mice. Red represents upregulated pathways; blue
oinflammatory molecules/growth factors (E), anti-inflammatory mediators (F),
base per million mapped reads (FPKM); *p% 0.05, **p% 0.01, ***p% 0.001,
frsf1bfl/fl mice. *p% 0.05, **p% 0.01, ***p% 0.001, EdgeR analysis.
NA-seq analysis. *p% 0.05, **p% 0.01, ***p% 0.001, Student’s t test.
incorporated by primary microglia from WT and Tnfrsf1b/ mice (K) were
% 0.001, one-way ANOVA, Tukey test; p^% 0.05, Student’s t test.
p; *p% 0.05, **p% 0.01, ***p% 0.001, one-way ANOVA, Tukey test; p^% 0.05,
Figure 5. Ablation of TNFR2 in LysMCre:Tnfrsf1bfl/fl Mice Results in Suppression of EAE
(A) Clinical course of EAE in Tnfrsf1bfl/fl and LysMCre:Tnfrsf1bfl/fl mice. n = 12–13/group from two experiments; ***p% 0.001, one-way ANOVA,Mann-Whitney test.
(B and C) Clinical course of EAE in bone-marrow-transplanted chimeric mice with TNFR2 ablation in Mo/MFs (LysMCre:Tnfrsf1bfl/fl/CD45.1) and corresponding
controls (Tnfrsf1bfl/fl/ CD45.1) (B), or in microglia (CD45.1/ LysMCre:Tnfrsf1bfl/fl) and corresponding controls (CD45.1/ Tnfrsf1bfl/fl) (C). n = 6–7/group;
*p% 0.05, one-way ANOVA, Mann-Whitney test.
(D and F) Flow cytometric analysis of the frequency (D) and absolute numbers (F) of infiltrated leukocytes at 20 dpi. n = 5/group; *p% 0.05, Student’s t test.
(E and G) Flow cytometric analysis of the frequency (E) and absolute numbers (G) of splenic leukocytes at 20 dpi. Mo/MFs are defined as
CD45hiCD11b+NK1.1Ly6GSSAlow. n = 8–11/group, *p% 0.05, Student’s t test.
(H) Representative flow plots of spinal cord microglia at 20 dpi.
(I–K) Quantification of percentage (I) and number (J) of microglia, and percentage of MHCII+ activated microglia (K). n = 5–6/group; *p% 0.05, Student’s t test.
All graph bars represent SEM.
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mice, EAE development and progression were suppressed
(Figure 5B), mirroring the profile of LysMCre:Tnfrsf1bfl/fl mice
(Figure 5A). Conversely, in CD45.1/LysMCre:Tnfrsf1bfl/fl mice,
EAE had accelerated onset and more severe progression (Fig-
ure 5C), similarly to Cx3cr1CreER:Tnfrsf1bfl/fl mice (Figure 1A). At
acutedisease (20dpi), thepercentagesof splenic cell populations
in LysMCre:Tnfrsf1bfl/fl mice were comparable with Tnfrsf1bfl/fl
mice (Figure 5E), but the numbers of CD4 andCD8T cells, B cells,
and MHCII+ activated B cells were reduced (Figure 5G).
The percentages of CNS-infiltrated cells were also unchanged
(Figure 5D), but the absolute number of CD4 T cells was mark-
edly lower (Figure 5F). In addition, the microglial response was
assessed, and although we did not see changes in cell number,
we detected a reduction in the frequency of MHCII+ activated
microglia in LysMCre:Tnfrsf1bfl/fl mice (Figures 5H–5K),
which could be a consequence of the reduced presence
of proinflammatory CD4 cells in the spinal cord. These results
indicate that TNFR2 ablation in Mo/MFs and not microglia ac-
counts for EAEsuppression in LysMCre:Tnfrsf1bfl/flmice, suggest-
ing that TNFR2 in peripheral myeloid cells is required for EAE
induction.
Ablation of TNFR2 in LysMCre:Tnfrsf1bfl/flMiceResults in
Impaired T Cell Proliferation and Effector Function in
the Spleen after EAE
T cell expansion and activation are key for EAE initiation (Sospe-
dra and Martin, 2005). Because we found reduced splenic T and
B cells, and reduced infiltrated CD4 T cells in LysMCre:Tnfrsf1bfl/fl
mice (Figures 5F and 5G), we investigated whether TNFR2
ablation from Mo/MFs impaired lymphocyte proliferation and
activation preventing EAE induction. In the spleen, we analyzed
proliferation at pre-disease (12 dpi) by Ki67 labeling and found in
LysMCre:Tnfrsf1bfl/fl mice a reduction in Ki67+ CD4 and CD8
T cells, but no difference in B cells (Figures 6A–6C). Effector
function was assessed at acute disease (20 dpi) by measuring
Th1 and Th17 cytokines. In splenic CD4 T cells, TNF production
did not change (Figure S7A), but IFNg and IL-17 were reduced in
LysMCre:Tnfrsf1bfl/fl mice (Figures 6D and 6E). No differences
were found in the CD8 population (Figures S7B and S7C).
On the contrary, IL-17 was increased in infiltrated CD4 cells
of LysMCre:Tnfrsf1bfl/fl mice (Figures 6D and 6G), with no differ-
ence in CD8 cells (Figure 6H; Figure S7E). IFNg and TNF did
not change (Figures S7D–S7F). Interestingly, Cx3cr1CreER:
Tnfrsf1bfl/fl mice showed a similar profile (Figure 2A), sug-
gesting that even minimal ablation of microglial TNFR2 as in
LysMCre:Tnfrsf1bfl/flmice may be sufficient to alter the CNS envi-
ronment and promote Th17 differentiation.
We went further to test whether reduced T cell expansion and
activation in LysMCre:Tnfrsf1bfl/fl mice could be associated with
increased presence of regulatory cells in the spleen. We did
not detect any changes in IL-10–producing B1a and B1b B reg-
ulatory cells (Bregs) (Figures S7G and S7H), but we observed an
increase in the frequency of CD25+FoxP3+ Tregs (Figures 6I and
6J), which could contribute to the suppressed T cell response.
Together these data indicate that ablation of TNFR2 in
peripheral Mo/MFs compromises T cell activation and function
resulting in inability to mount an efficient immune response and
initiate EAE.206 Cell Reports 18, 198–212, January 3, 2017Ablation of TNFR2 in LysMCre:Tnfrsf1bfl/flMiceResults in
Myelin Preservation and Neuroprotection in EAE
To investigate whether the improved functional outcome in
LysMCre:Tnfrsf1bfl/fl mice corresponded to reduced myelin
and axon pathology, we assessed white matter damage in
the spinal cord by Luxol fast blue (LFB) staining. At 50 dpi,
LysMCre:Tnfrsf1bfl/fl mice showed reduced demyelination (Fig-
ures 7A and 7B), accompanied by a higher number of
Olig2+PDGFRa+ OPCs (Figure 7C). Electron microscopy (EM)
analysis of remyelination showed LysMCre:Tnfrsf1bfl/fl mice to
have a higher number of remyelinated axons in the spinal cord
(Figures 7D and 7E), which, together with the higher presence
of OPCs, suggests that repair mechanisms are more efficient
in these mice. Evaluation of axonal damage showed significant
neuroprotection in LysMCre:Tnfrsf1bfl/fl mice, with more intact
axons (Figures 7F and 7G) and reduced accumulation of degen-
erated axons (Figures 7F and 7H), which correlated with the
lower clinical scores at chronic EAE.
DISCUSSION
In the present study we uncover a dichotomy of functions
for microglial versus monocyte/macrophagic TNFR2 in EAE
pathophysiology. We demonstrate that TNFR2 in microglia is
protective by providing signals to contain neuroinflammation,
whereas TNFR2 in Mo/MFs is detrimental by driving immune
activation and EAE initiation.
Microglia and Mo/MFs are the main effectors of the innate
immune response and, as such, perform homeostatic and sur-
veillance functions sharing similar roles in different compart-
ments, the CNS or the periphery (Ginhoux and Jung, 2014; Prinz
et al., 2014). This explains why much of the molecular machinery
is common to the two populations, despite their distinct develop-
mental origin (Ginhoux et al., 2010). Exceptions to this rule are
signature genes that have been recently identified as primarily
expressed in one or the other, such as P2ry12 and Cx3cr1
found almost exclusively in microglia, and P2rx4, Ccr2, and Ifitm
genes found uniquely in Mo/MFs (Hickman et al., 2013). Capital-
izing on this genetic diversity and developmental origin, the
Cx3Cr1CreER+/mouse line has allowed to specifically target mi-
croglia when using a tamoxifen induction protocol devised to
take advantage of the different turnover rates of myeloid cells
(Goldmann et al., 2013; Parkhurst et al., 2013; Yona et al.,
2013). With this strategy we generated Cx3cr1CreER:Tnfrsf1bfl/fl
mice to dissect the role of microglial TNFR2 in EAE. Comparative
transcriptome analysis shows that microglia are the neural cells
with the highest expression of TNFR2 (http://web.stanford.edu/
group/barres_lab/cgi-bin/igv_cgi_2.py?lname=Tnfrsf1b) (Zhang
et al., 2014). Because tmTNF, the activating ligand of TNFR2,
is protective in EAE (Brambilla et al., 2011; Taoufik et al.,
2011), and in vitro evidence showed that TNFR2 is able to acti-
vate antiinflammatory signals (Veroni et al., 2010), we hypothe-
sized that microglial TNFR2 could be the executor, at least
in part, of tmTNF beneficial functions in vivo. In support of
this hypothesis, Cx3cr1CreER:Tnfrsf1bfl/fl mice developed EAE
earlier, showing signs of paralysis more than 2 days in advance
of Tnfrsf1bfl/fl controls. This was accompanied by elevated
numbers and cellular activation of microglia at disease onset,
Figure 6. Ablation of TNFR2 in LysMCre:Tnfrsf1bfl/flMice Results in Impaired T Cell Proliferation and Effector Function in the Spleen after EAE
(A and B) Representative flow plots of Ki67 expression in CD4 (A) and CD8 (B) T cells in Tnfrsf1bfl/fl and LysMCre:Tnfrsf1bfl/fl mice at 12 dpi.
(C) Quantification of Ki67+ splenic lymphocytes. n = 4–5/group; *p% 0.05, Student’s t test.
(D) Representative flow plots of cytokine expression in CD4 T cells from spleen and spinal cord at 20 dpi.
(E–H) Quantification of cytokine expression in CD4 (E, G) and CD8 (F, H) T cells; n = 3–6/group; *p% 0.05, **p% 0.01, Student’s t test.
(I) Representative flow plots of splenic Tregs in Tnfrsf1b
fl/fl and LysMCre:Tnfrsf1bfl/fl mice at 20 dpi.
(J) Quantification of splenic Treg frequency. n = 4–5/group; *p% 0.05, Student’s t test.
All graph bars represent SEM. See also Figure S6.paralleled by a higher CNS influx of activated immune cells. This
indicates that TNFR2-dependent signals in microglia suppress
neuroinflammation, and without them the CNS is more vulner-
able to immune-inflammatory attack from the periphery. AsEAE progresses, the clinical profiles of the two genotypes
converge, and this may be due to more immune cells flooding
the CNS and overcoming the antiinflammatory ‘‘barrier’’ set
by microglial TNFR2. Nevertheless, our data underscore theCell Reports 18, 198–212, January 3, 2017 207
Figure 7. Ablation of TNFR2 in LysMCre:Tnfrsf1bfl/fl Mice Results in Reduced Demyelination and Improved Remyelination and Neuro-
protection in EAE
(A) Assessment of demyelination in the spinal cord of Tnfrsf1bfl/fl and LysMCre:Tnfrsf1bfl/fl mice by LFB staining. Left: contoured areas show regions of de-
myelinated white matter. Scale bars, 200 mm. Right: 3D reconstructions of the demyelinated areas (red).
(B) Quantification of the demyelinated white matter volume. n = 3–5/group; **p% 0.01, Student’s t test.
(C) Quantification of Olig2+PDGFRa+ OPCs in the spinal cord. n = 3–5/group; **p% 0.01, Student’s t test.
(D) Representative electron micrographs of the spinal cord at 50 dpi showing remyelinated axons (red arrows). Scale bar, 1 mm.
(E) Quantification of remyelinated axons. n = 4–5/group; *p% 0.05, Student’s t test.
(F) Toluidine blue staining of spinal cord sections from naive and 50 dpi mice. Red arrows indicate degenerated axons. Scale bar, 10 mm.
(G and H) Quantification of myelinated (G) and degenerated (H) axons. n = 4–5/group; *p% 0.05, **p% 0.01, Student’s t test.
All graph bars represent SEM.protective role of microglial TNFR2 in the early stage of disease,
which seems to participate in the immediate response of the
CNS to alterations of its homeostasis.208 Cell Reports 18, 198–212, January 3, 2017To gain insight into the mechanisms of microglial TNFR2-
dependent regulation of EAE, we performed RNA-seq analysis
of the microglial transcriptome of Cx3cr1CreER:Tnfrsf1bfl/fl and
Tnfrsf1bfl/fl mice at disease onset. The picture that emerged is
twofold. First, TNFR2 is crucial for microglial homeostatic func-
tions. For example, TNFR2 ablation causes downregulation of
the microglia-specific gene Trem2, which is necessary for innate
immunity, phagocytosis, and resolution of inflammation (Neu-
mann and Takahashi, 2007). Loss-of-function mutations of
Trem2 in humans lead to neurodegenerative disease, including
a form of late-onset Alzheimer’s disease (Guerreiro et al., 2013;
Jonsson et al., 2013), where the Trem2 mutation has been sug-
gested to disrupt microglial interaction with damaged neurons
preventing their phagocytosis (Walter, 2016). Our in vitro data
suggest that Trem2-dependent phagocytosis may be regulated
by TNFR2. Indeed, without TNFR2, phagocytosis is drastically
impaired, as is the expression of Trem2. The impaired ability of
TNFR2-deficient microglia to respond to danger signals is re-
flected in the altered expression of the sensome genes, espe-
cially those required for detection of endogenous signals.
This includes P2 purinergic receptors, which respond to ATP
released by degenerating cells (Rodrigues et al., 2015), and
Siglecs that keep microglia in a silent homeostatic status
(Linnartz-Gerlach et al., 2014). Together, these data indicate
that TNFR2 is an important signal for host defense and proper
microglial response to injury.
The second key finding of the RNA-seq analysis is that TNFR2-
ablated microglia display a more invasive and proinflammatory
phenotype. For instance, genes encoding cell adhesion mole-
cules were upregulated in microglia lacking TNFR2. One
example is Vcam-1. VCAM-1+ microglial cells have been identi-
fied at the edges of MS lesions in the proximity of oligodendro-
cyte cell bodies where oligodendrocyte loss occurs, suggesting
that this contact may be detrimental to their survival (Peterson
et al., 2002). Integrins (Itgal, Itga4) were also upregulated, and
because they are known to modulate microglial migration and
activation during neuroinflammation (Milner and Campbell,
2002), this further supports the idea that lack of TNFR2 exacer-
bates the microglial proinflammatory phenotype. This is also
indicated by the upregulation of proinflammatory genes,
such as chemokines. The elevated chemokine production by
TNFR2-deficient microglia can help explain the increased influx
of immune cells in Cx3cr1CreER:Tnfrsf1bfl/fl mice. This may also
be driven by a concomitant increase in BBB permeability, which
is suggested by the early downregulation of ZO-1 expression.
ZO-1 is decreased as early as 12 days after EAE induction, indi-
cating that BBB alterations dependent on dysregulated TNFR2-
ablated microglia could indeed be one of the earliest, and
perhaps most critical, drivers of the exacerbated pathology in
Cx3cr1CreER:Tnfrsf1bfl/fl mice. In addition, the upregulation of
vascular endothelial growth factor A (Vegfa) found in the RNA-
seq screening also supports the idea of a more permeable
BBB. Indeed, several reports have shown that CNS-derived
VEGFA is implicated in BBB disruption, because its ablation pre-
vents BBB breakdown and lymphocyte influx in EAE (Argaw
et al., 2009, 2012). Another interesting finding from the RNA-
seq analysis is the upregulation of Hgf in microglia of
Cx3cr1CreER:Tnfrsf1bfl/fl mice. HGF has been described as the
primary microglial-derived chemotactic factor for OPCs, pro-
moting their proliferation and migration to the site of demyelin-
ation (Lalive et al., 2005). This fits well with our data showingincreased presence of OPCs in Cx3cr1CreER:Tnfrsf1bfl/fl mice
with chronic disease, where Hgf may serve as a reparative
mechanism.
For a full understanding of myeloid TNFR2 function, the next
step was to address the role of TNFR2 in peripheral Mo/MFs,
for which we used LysMCre:Tnfrsf1bfl/fl mice. Because infiltrating
monocytes and resident microglia both differentiate into macro-
phages that contribute to demyelination in EAE, the expectation
was for monocyte/macrophagic TNFR2 to engage processes
similar to those in microglia, resulting in worsening of the clinical
outcome as in Cx3cr1CreER:Tnfrsf1bfl/fl mice. Unexpectedly, our
data showed the opposite, with LysMCre:Tnfrsf1bfl/fl mice being
protected from EAE because of their inability to mount an effi-
cient autoimmune response. This was dependent on impairment
of two key steps in T cell activation: expansion and differentia-
tion. Mo/MFs can regulate these processes by presenting anti-
gens and secreting cytokines (Hume, 2008; Wang et al., 2015)
such as transforming growth factor b1 (TGF-b1) and IL-6. The
concerted action of TGF-b1 and IL-6 drives T cell expansion
and also differentiation from naive to a Th17 phenotype (Veld-
hoen et al., 2006), which is the key encephalitogenic popula-
tion in EAE. Because both phenomena are suppressed in
LysMCre:Tnfrsf1bfl/fl mice, it is possible that TNFR2 regulates
the expression of these cytokines in Mo/MFs. This idea is sup-
ported by our RNA-seq data, where we saw a reduction of
both TGFb1 and IL-6 signaling in TNFR2-deficient microglia. If
this occurred also in Mo/MFs, it would suggest that the opposite
functions of microglial versus monocyte/macrophagic TNFR2
may depend not necessarily on the activation of distinct path-
ways, but on the engagement of the same pathways that lead
to opposite effects because of the different compartments
from where the cells originate.
TNFR2 in Mo/MFs could also be regulating T cell expansion
and differentiation indirectly by affecting regulatory T cells. Treg
frequency is increased in LysMCre:Tnfrsf1bfl/fl mice, and their
powerful suppressive activity may contribute to dampening
T cell effector function in EAE. In addition to these mechanisms,
we cannot exclude the possibility that macrophagic TNFR2
may act via B cell modulation. Indeed, we showed that
LysMCre:Tnfrsf1bfl/fl mice have reduced MHCII-expressing B
cells in the spleen. Their compromised antigen presentation ca-
pacity could be in part responsible for the reduced EAE severity.
As far as tmTNF-expressing cells that interact with microglia
and Mo/MFs to carry out TNFR2 functions, they may differ in
physiological and pathological conditions. In the normal CNS,
microglial TNFR2 will exert its beneficial homeostatic functions
likely via contact with tmTNF-expressing microglia and astro-
cytes. In injury conditions, the repertoire of possible microglial
TNFR2 activators widens as all CNS cells (including neurons)
and infiltrating immune cells upregulate TNF production (Pro-
bert, 2015). Microglia, however, remain the most efficient TNF
producers (Olmos and Llado´, 2014), suggesting that much of
the tmTNF-TNFR2 protective signaling may be driven by a mi-
croglial cell–autonomous process both under physiological and
pathological conditions. In the periphery, TNFR2-expressing
Mo/MFs may encounter their tmTNF ligand on virtually all leuko-
cytes, particularly in disease conditions, but also on endothelial
and stromal cells, such as fibroblasts and pericytes. AmongCell Reports 18, 198–212, January 3, 2017 209
leukocytes, dendritic cells may be important partners of TNFR2-
expressing Mo/MFs, because they have been shown to play
important roles in innate immune regulation precisely via tmTNF
(Xu et al., 2007).
Overall, our study fits within the now accepted model that
in pathological conditions the contribution of microglia and
peripheral myeloid cells to disease etiology, progression, and
resolution may diverge (Shemer and Jung, 2015). In EAE, for
example, Yamasaki and colleagues elegantly showed that
peripherally derived macrophages associate with nodes of
Ranvier and initiate demyelination, whereas microglia take on
a protective function by clearing cellular debris (Yamasaki
et al., 2014). In this context, we propose TNFR2 as one of the
possible effectors of this dual behavior, because TNF produc-
tion and TNFR2 expression are highly upregulated following
EAE in myeloid cells.
Finally, our work further highlights the complexity of TNF func-
tion in neuroimmune disease. Not only does TNF have opposite
roles whether in soluble or transmembrane form, with solTNF be-
ing proinflammatory and tmTNF protective, but so does its re-
ceptor TNFR2 depending on the location in central or peripheral
myeloid cells. This must be taken into account from a clinical
perspective, because strategies enhancing TNFR2 signaling
have been proposed as therapeutic avenues in neurodegenera-
tive diseases (Dong et al., 2016; Maier et al., 2013). TNFR2 ago-
nists specifically targeted to the CNS via ad hoc delivery systems
at the appropriate time may be a viable pharmacological
approach provided their effects on peripheral immune activation
are minimized.
EXPERIMENTAL PROCEDURES
Mice
Adult (2–4 months) female and male mice were used in this study. Mice
with conditional ablation of the TNFR2 gene (Tnfrsf1b) were generated by
crossing Cx3cr1CreER;EYFP+/ (Jackson Laboratory, 021160) and LysMCre+/
mice (Jackson Laboratory, 004781) with Tnfrsf1bfl/fl mice. Tnfrsf1bfl/fl mice
were obtained by breeding C57BL/6NTac-Tnfrsf1btm1a(EUCOMM)Wtsi/Ics mice
(European Mouse Mutant Archive) with an Flp recombinase (FLP) deleter
(Jackson Laboratory, 009086) to remove the flippase recognition target
(FRT)-flanked neomycin cassette. In all experiments, Tnfrsf1bfl/fl littermates
were used as controls. In Cx3cr1CreER:Tnfrsf1bfl/fl mice, Cre recombinase
was induced by five daily intraperitoneal (i.p.) tam injections (2 mg/mouse/
day) followed by a 28-day waiting period. Control mice received the same
treatment. Rosa26tdTomato+/ reporter mice (007914) and CD45.1 congenic
C57BL/6 mice (002014) were obtained from Jackson Laboratory. Colonies
were housed in the virus/antigen-free Animal Core Facility of TheMiami Project
to Cure Paralysis, with a 12-hr light-dark cycle, controlled temperature and
humidity, and were provided with water and food ad libitum. Experiments
were performed according to protocols approved by the Institutional Animal
Care and Use Committee of the University of Miami.
Behavioral Assessments
Open-field and Rotorod tests were performed as previously described (Mad-
sen et al., 2016a).
Induction of Experimental Autoimmune Encephalomyelitis
Active EAE was induced with myelin oligodendrocyte glycoprotein (MOG35–55)
peptide as previously described (Brambilla et al., 2014).
Isolation of Leukocytes from Spinal Cord and Spleen
Cells were isolated as previously described (Brambilla et al., 2014).210 Cell Reports 18, 198–212, January 3, 2017Bone Marrow Transplantation
Bone marrow transplantation was performed as previously described (Ash-
baugh et al., 2013).
Luxol Fast Blue Staining and Quantification of Demyelinated White
Matter Volume
Paraformaldehyde (PFA)-fixed segments of the spinal cord were paraffin
embedded, sectioned into 15-mm-thick cross sections with a Leica RM 2135
microtome, and stained with Luxol fast blue (LFB) and H&E. Twenty serial
sections at 120 mm intervals were used to estimate the demyelinated white
matter volume. Demyelinated areas were outlined with an Olympus BX51
microscope, and demyelinated white matter volume was quantified with
Stereoinvestigator software (MicroBrightfield). 3D reconstructions of the
demyelinated spinal cord were performed on the same serial sections with
Neurolucida software (MBF Bioscience).
Toluidine Blue Staining and ElectronMicroscopy Tissue Preparation
Toluidine blue staining and electron microscopy tissue preparation were per-
formed as previously described (Brambilla et al., 2014).
Statistical Analysis
Statistical analysis of EAE clinical course was carried out with the Mann-Whit-
neyU test. For analysis of RNA-seq data, see Supplemental Experimental Pro-
cedures. All other data were analyzed by one-way ANOVA followed by Tukey
test for multiple comparisons. In single comparisons, Student’s t test was
applied. The p values %0.05 were considered statistically significant. Data
were expressed as the average of multiple determinations ± SEM. Statistical
analyses were performed with Prism software.
For all other methods, protocols, and materials, see Supplemental Experi-
mental Procedures.ACCESSION NUMBERS
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